1. Home
  2. IPHA vs AMWL Comparison

IPHA vs AMWL Comparison

Compare IPHA & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

BUY

Current Price

$1.44

Market Cap

165.3M

Sector

Health Care

ML Signal

BUY

Logo American Well Corporation

AMWL

American Well Corporation

SELL

Current Price

$12.10

Market Cap

179.6M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
IPHA
AMWL
Founded
1999
2006
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
179.6M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
IPHA
AMWL
Price
$1.44
$12.10
Analyst Decision
Strong Buy
Hold
Analyst Count
3
7
Target Price
$6.67
★ $12.80
AVG Volume (30 Days)
55.5K
★ 85.1K
Earning Date
09-17-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.06
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$390.56
N/A
Revenue Next Year
$143.06
$3.66
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$3.71
52 Week High
$2.71
$14.19

Technical Indicators

Market Signals
Indicator
IPHA
AMWL
Relative Strength Index (RSI) 31.76 41.95
Support Level $1.34 $11.99
Resistance Level $1.83 $13.92
Average True Range (ATR) 0.10 0.68
MACD -0.01 -0.14
Stochastic Oscillator 6.76 5.93

Price Performance

Historical Comparison
IPHA
AMWL

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About AMWL American Well Corporation

American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.

Share on Social Networks: